Featured 13F manager
DME Capital Management David Einhorn
New York, NY 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $3.9B
- 46 holds
- 2026 Q2
- +22.5% QoQ
- Top 5 38.2%
David Einhorn files DME Capital Management as a Form 13F. The latest book is 2026 Q2 at $3.9B, up 22.5% QoQ, led by Green Brick Partners, Fluor, and Core Natural Resources.
Portfolio
top 5 38.2% · top 10 52.8%
- GRBK - Green Brick Partners 19.4%
- FLR - Fluor 6.2%
- CNR - Core Natural Resources 4.7%
- BHF - Brighthouse Finl 4.6%
- ACHC — 3.3%
- PENN - Penn Entertainment 3.2%
- FBIN - Fortune Brands 3.1%
- PCG - Pg And E 2.9%
- CNC - Centene Del 2.7%
- PKG - Graphic Packaging 2.7%
- SNX - Td Synnex 2.6%
- TEVA - Teva Pharmaceutical Inds 2.5%
- Other 42.1%
AUM over time
Book
| GRBK - Green Brick Partners | Hold | 17,418,668 | $30.33 | $528M | — | — | |
| BHF - Brighthouse Finl | Reduce −3.4% | 3,787,688 | $51.80 | $196M | −132,312 | +$19M | |
| TECK - Teck Resources · CL B | Reduce −25.0% | 3,395,898 | $28.82 | $98M | −1,131,966 | −$15M | |
| Change Healthcare | Add +1.4% | 3,636,805 | $21.38 | $78M | +50,000 | +$3M | |
| Holding | Reduce −46.2% | 815,000 | $94.12 | $77M | −699,855 | −$47M | |
| GPN - Global Pmts | New | 506,000 | $135.18 | $68M | +506,000 | +$68M | |
| CC - Chemours | Reduce −25.0% | 1,741,814 | $33.56 | $58M | −580,605 | −$9M | |
| CPRI - Capri | Add +45.7% | 883,000 | $64.91 | $57M | +277,000 | +$28M | |
| ODP1 - The Odp | Add +25.3% | 1,437,590 | $39.28 | $56M | +290,658 | +$10M | |
| CEIXEUR - Consol Energy | Reduce −11.4% | 1,877,021 | $22.71 | $43M | −242,008 | −$13M | |
| SLV - Ishares Silver Tr | Hold | 1,558,000 | $21.51 | $34M | — | — | |
| REZI - Resideo Technologies | Reduce −14.3% | 1,169,383 | $26.03 | $30M | −195,680 | −$3M | |
| GPRO - Gopro · CL A | Reduce −20.0% | 2,931,900 | $10.31 | $30M | −733,000 | −$4M | |
| LIVN - Livanova | Add +92.1% | 341,000 | $87.43 | $30M | +163,500 | +$16M | |
| VSXY - Victorias Secret And | Add +602.8% | 454,881 | $55.54 | $25M | +390,153 | +$22M | |
| GLD - Spdr Gold Tr | Hold | 115,880 | $170.96 | $20M | — | — | |
| Jack In The Box | Add +41.8% | 211,024 | $87.48 | $18M | +62,224 | +$4M | |
| KD - Kyndryl | New | 922,400 | $18.10 | $17M | +922,400 | +$17M | |
| PKG - Graphic Packaging | Hold | 832,270 | $19.50 | $16M | — | — | |
| INTC - Intel | New | 309,500 | $51.50 | $16M | +309,500 | +$16M | |
| Discovery | New | 652,000 | $23.54 | $15M | +652,000 | +$15M | |
| SONO - Sonos | Add +20.6% | 438,680 | $29.80 | $13M | +75,000 | +$1M | |
| PLBY Group | Hold | 410,000 | $26.64 | $11M | — | — | |
| Reduce −50.0% | 243,750 | $43.22 | $11M | −243,750 | −$19M | ||
| LKFT - Galapagos | New | 185,000 | $55.13 | $10M | +185,000 | +$10M | |
| CNXC - Concentrix | Reduce −79.5% | 54,436 | $178.61 | $10M | −211,573 | −$37M | |
| NWSA - NEWS · CL B | Hold | 361,291 | $22.50 | $8M | — | — | |
| Neubase Therapeutics | Hold | 2,727,027 | $2.81 | $8M | — | — | |
| GPOR - Gulfport Energy | Hold | 106,054 | $72.02 | $8M | — | — | |
| Danimer Scientific · CL A | Reduce −65.2% | 821,000 | $8.52 | $7M | −1,537,172 | −$32M | |
| Talis Biomedical | New | 1,569,300 | $4.01 | $6M | +1,569,300 | +$6M | |
| CIVI - Civitas Resources | New | 118,218 | $48.97 | $6M | +118,218 | +$6M | |
| ASTS - Ast Spacemobile · CL A | Hold | 570,000 | $7.94 | $5M | — | — | |
| Freyr Battery | Reduce −50.0% | 350,000 | $11.18 | $4M | −350,000 | −$3M | |
| Playstudios · CLASS A | Reduce −1.7% | 963,018 | $3.95 | $4M | −16,782 | −$665K | |
| Waverley Capital Acquis | Hold | 350,000 | $9.89 | $3M | — | — | |
| Finserv Acquisition Ii | Hold | 315,000 | $9.86 | $3M | — | — | |
| CNX - Cnx Res | Hold | 222,715 | $13.75 | $3M | — | — | |
| GANX - Gain Therapeutics | Hold | 546,560 | $5.43 | $3M | — | — | |
| Panacea Acquisition Ii · CL A | Hold | 275,000 | $9.70 | $3M | — | — | |
| SATS - Echostar · CL A | Reduce −92.7% | 75,000 | $26.35 | $2M | −952,153 | −$24M | |
| FLNA - Cassava Sciences | New | 40,620 | $43.70 | $2M | +40,620 | +$2M | |
| 23andme · CLASS A | New | 98,122 | $6.65 | $653K | +98,122 | +$653K | |
| NUVB - Nuvation Bio · CL A | Hold | 34,995 | $8.49 | $297K | — | — | |
| Proterra | New | 15,070 | $8.83 | $133K | +15,070 | +$133K |
Exits / last held
Not current holdings · last reported size, unchanged · gone vs 2021 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| AER - Aercap | Exit | 0 | $57.81 | $31M | −528,858 | −$31M | |
| Fubotv | Exit | 0 | $23.96 | $8M | −322,580 | −$8M | |
| Extraction Oil & Gas | Exit | 0 | $56.45 | $6M | −99,485 | −$6M | |
| Holding | Exit | 0 | $10.10 | $4M | −373,104 | −$4M | |
| EXPE - Expedia Group | Exit | 0 | $163.90 | $3M | −20,000 | −$3M | |
| Stryve Foods · CLASS A | Exit | 0 | $5.35 | $803K | −150,000 | −$803K | |
| Altimeter Growth 2 · CL A | Exit | 0 | $9.89 | $563K | −56,908 | −$563K | |
| Adamis Pharmaceuticals | Exit | 0 | $0.9680 | $283K | −292,366 | −$283K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 46 | $3.9B | +22.5% | 13F-HR | 8/14/2026 | 000117266126003786 |
| 2026 Q1 | 45 | $3.2B | +12.0% | 13F-HR | 5/15/2026 | 000117266126002341 |
| 2025 Q4 | 41 | $2.8B | +12.1% | 13F-HR | 2/17/2026 | 000117266126001122 |
| 2025 Q3 | 37 | $2.5B | +9.3% | 13F-HR | 11/14/2025 | 000117266125005032 |
| 2025 Q2 | 34 | $2.3B | +17.8% | 13F-HR | 8/14/2025 | 000117266125003351 |
| 2025 Q1 | 33 | $2B | +1.5% | 13F-HR | 5/15/2025 | 000117266125002307 |
| 2024 Q4 | 36 | $1.9B | −19.1% | 13F-HR | 2/14/2025 | 000117266125001165 |
| 2024 Q3 | 38 | $2.4B | +17.6% | 13F-HR | 11/14/2024 | 000117266124005240 |
| 2024 Q2 | 39 | $2B | −6.5% | 13F-HR | 8/14/2024 | 000117266124003549 |
| 2024 Q1 | 42 | $2.2B | — | 13F-HR | 5/15/2024 | 000117266124002489 |
| 2023 Q4 | 40 | $2B | +16.3% | 13F-HR | 2/14/2024 | 000117266124001512 |
| 2023 Q3 | 39 | $1.8B | −17.4% | 13F-HR | 11/14/2023 | 000117266123004012 |
| 2023 Q2 | 41 | $2.1B | +15.9% | 13F-HR | 8/14/2023 | 000117266123003174 |
| 2023 Q1 | 39 | $1.8B | +27.4% | 13F-HR | 5/15/2023 | 000117266123002282 |
| 2022 Q4 | 42 | $1.4B | +2.3% | 13F-HR | 2/14/2023 | 000117266123001336 |
| 2022 Q3 | 42 | $1.4B | +9.8% | 13F-HR | 11/14/2022 | 000117266122002565 |
| 2022 Q2 | 47 | $1.3B | −18.3% | 13F-HR | 8/15/2022 | 000117266122002019 |
| 2022 Q1 | 52 | $1.6B | −10.0% | 13F-HR | 5/16/2022 | 000117266122001474 |
| 2021 Q4 | 57 | $1.7B | +17.2% | 13F-HR | 2/14/2022 | 000117266122000884 |
| 2021 Q3 | 58 | $1.5B | — | 13F-HR | 11/15/2021 | 000117266121002370 |
About
DME Capital Management
20 processed 13Fs on this site · 2021 Q3–2026 Q2